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Abstract: Background And Objective: Periodontitis is an inflammatory disease causing bone loss, and is a primary cause 
of tooth loss. Gingival fibroblasts are readily available with minimal donor site morbidity and may be ideal for   
tissue engineering efforts in regenerating lost alveolar bone. Dexamethasone (Dex) is commonly employed for in vitro  
osteogenic induction of a variety of cells, but its effect on human gingival fibroblasts (HGF) is still controversial.   
Therefore, the aim of our study was to investigate the osteogenic differentiation of HGF following Dex treatment. 
Methods: Cultured HGFs were exposed to osteogenic medium containing a wide range of Dex concentrations (0.01-10 
M). The osteogenic phenotype was assessed based on changes in alkaline phosphatase (ALP) activity, the mRNA   
expression of selected extracellular matrix proteins critical for mineralization and the extent of extracellular mineralization 
(Von Kossa staining and Ca-content).  
Results: All assays showed a consistent and maximal osteogenic effect of Dex on HGF at 0.1 and 0.5 M (weeks 3 and 4), 
as evidenced by significant osteopontin and osteocalcin expression and mineralization. Longer cultures (week 4) also 
yielded positive osteogenic effect of Dex at 0.01 M. Moreover, ALP activity was significantly stimulated at 0.1 and 0.5 
μM Dex initially after one week, but ALP was subsequently reduced under Dex. Higher Dex concentrations caused down 
regulation of osteogenic effects observed at the optimal (0.1-0.5 M) concentrations.  
Conclusion: Under appropriate osteogenic conditioning, Dex treated HGFs could be a potential source of cells for   
cell-based therapy for periodontal bone regeneration.  
Keywords: Periodontitis, gingival fibroblasts, dexamethasone, osteogenic differentiation, bone regeneration. 
INTRODUCTION 
Periodontal diseases results in irreversible loss of alveo-
lar bone [1]. The loss of supporting bone around roots can be 
partially remedied using various grafting materials, with 
autologous grafts being the most successful among them [2]. 
Guided tissue regeneration is another approach that can be 
used in regeneration of lost alveolar bone [3]. Nonetheless, 
the success of both techniques is based on different systemic 
and local factors including: defect type, age, genetics, and 
disease predisposition [2, 3]. To overcome the limitations 
related to the current treatments, bone tissue engineering   
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including cell-based therapy has been proposed as an alterna-
tive therapeutic solution for periodontal disease [4]. That 
approach, however, is often hampered by the need for large 
quantities of tissue-specific cells when the cell-based ap-
proach is considered.  
Gingival fibroblasts (GF) and periodontal ligament 
(PDL) cells form the major cellular components of the 
periodontal connective tissue and are responsible for ex-
tracellular matrix production [5]. It has been hypothesized 
that PDL cells may differentiate into osteoblast-like cells 
during periodontal regeneration and may contribute to alveo-
lar bone formation [6]. The localization of mRNA transcripts 
traditionally associated with mineralized tissue such as ALP, 
osteopontin (OPN), and osteocalcin (OCN) were stronger in 
PDL compared to gingival tissue [7, 8]. Accordingly, the 
PDL has been considered a promising source of cells for 
regenerating alveolar bone, due to their proven osteogenic 140     The Open Dentistry Journal, 2011, Volume 5  Mostafa et al. 
differentiation potential [9]. On the other hand, GF cells are 
more accessible with significantly less donor-site morbidity 
compared to PDL cells, which necessitates tooth extraction 
for harvesting. Thus, GF might be a more suitable cell type 
that might be used for periodontal regeneration, but their 
ability to differentiate into an osteogenic phenotype had not 
been fully established. 
The successful use of GF for alveolar bone regeneration 
would require those cells to be differentiated into an os-
teogenic pathway before transplantation. Osteogenesis in 
pluripotent cells can be achieved using growth factors, such 
as Bone Morphogenetic Proteins (BMPs) or hormones such 
as Dexamethasone (Dex) [10]. The latter is a more accept-
able agent for the in vitro induction of osteogenesis, given its 
low cost and stability in the physiological environment. Dex 
is a synthetic glucocorticoid, that has an anti-inflammatory 
and immunosuppressant effect in vivo [11]. Dex is often used 
for  in vitro osteogenic induction of bone marrow cells in 
combination with ascorbic acid and ß-glycerolphosphate 
[10], as it mediates ALP synthesis and activity in osteoblasts 
[12]. In previous studies, Dex has been used for in vitro os-
teogenic differentiation and mineralized matrix formation in 
human PDL cells, but its effect on HGF remains unclear [13-
15]. Dex was shown to up-regulate osteogenic biomarkers in 
HGF in one report [15], but not others [13, 14]. No consis-
tent effect of Dex on HGF has been reported, however, only 
limited concentrations or single dosages were studied in 
those reports [13-15]. Accordingly, it can be hypothesized 
that the concentration of Dex used to potentially induce os-
teogenic differentiation of HGF could be expected to play a 
significant role in those studies. 
Thus, we examined the osteogenic potential of Dex on 
HGF cells to determine its utility for cell-based bone regen-
erative therapies, such as alveolar bone regeneration. In the 
current study, we evaluated the effect of osteogenic media 
containing a wide range of Dex concentrations to elicit HGF 
osteogenic differentiation and mineralization in vitro.  
MATERIALS AND METHODS 
Materials 
Dulbecco’s Modified Eagle Medium (DMEM), penicil-
lin/streptomycin (10,000 U/mL/10,000 μg/mL solutions), 
fetal bovine serum (FBS) and Hank’s Balanced Salt Solution 
(HBSS) were from GIBCO (Grand Island, NY). The Cy-
QUANT cell proliferation kit from Molecular Probes (Port-
land, OR) was used to quantify the DNA concentrations in 
HGF cell lysates. Hexosaminidase substrate p-nitrophenol 
glucoseaminide, ALP substrate p-nitrophenol phosphate (p-
NPP), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT), Dex, ß-glycerophophate (ß-GP), and ascor-
bic acid were obtained from Sigma (St. Louis, MO).  
Isolation and Culture of Gingival Fibroblasts 
The HGF cell line was established from gingival biopsies 
that were obtained from healthy interdental papilla and 
placed in a 'biopsy' medium, containing DMEM with 100 
U/mL penicillin, and 100 g/mL streptomycin. Informed 
consent was obtained from all donors and the research proto-
col was approved by our University Health Research Ethics 
Board. Gingival tissues, were diced into small pieces, seeded 
onto glass slides in cell culture plates, and incubated with 
basic medium (DMEM, 10% FBS, 100 U/mL penicillin, and 
100 μg/mL of streptomycin) at 37°C in a humidified atmos-
phere of 5% CO2. When cellular outgrowth from the gingival 
explants was confluent following 2-3 weeks of culture, they 
were transferred to 75 cm
2 tissue culture flasks using 0.08% 
trypsin/0.04% ethylenediamine-tetraacetic acid.  
Osteogenic Treatment with Dex 
HGFs at passage 4 were grown in 48 well plates at an ini-
tial seeding density of 2.5 x 10
3 cells/well. The experimental 
groups were treated with osteogenic media containing basic 
medium, with the addition of 10 mM ß-GP and 50 g/ml 
ascorbic acid to stimulate mineralization. Cells were then 
divided into five subgroups based on the Dex concentration 
used (0.01, 0.1, 0.5, 1.0 and 10 M). The control group was 
treated with basic medium alone. Cell culture medium was 
changed 2 times per week. After different periods of incuba-
tion (weeks 1, 2, 3, and 4), replicates of HGF cultures were 
analyzed for cell viability (MTT), proliferation (growth 
curve and DNA assay), differentiation (ALP activity and 
gene expression analysis of select bone extracellular matrix 
proteins), and calcified matrix synthesis (Von Kossa staining 
and quantification of Ca-content). 
MTT Assay for Cell Viability 
The MTT assay is based on the conversion of a tetra-
zolium salt (MTT) into a blue formazan in the viable cells. 
Briefly, MTT was dissolved in HBSS (5 mg/mL) and a 100 
μL of MTT solution was added into each well containing 0.5 
mL medium in 48-well plates. After 2 hours of incubation, 
the medium was replaced with 500 L of dimethylsulfoxide 
to dissolve the formed formazan crystals. The absorbance of 
the colored solution was quantified at 570 nm [16]. 
Hexosaminidase Assay for Cell Growth 
Changes in cell number were determined to evaluate 
HGF cell growth as a function of Dex concentration in os-
teogenic supplements. In brief, 0.15 mM p-nitrophenol glu-
coseaminide was dissolved in 0.1 M citrate buffer (pH 5.0) 
and mixed with an equal volume of 0.5% Triton X-100 in 
water. Then, 100 μL of the substrate solution was added to 
HGF cells into 96-well plates. After 4 hours of incubation, 
enzymatic activity was blocked by the adding 50 mM gly-
cine buffer containing 5 mM Ethylenediaminetetraacetic acid 
and absorbance was quantified at 405 nm. Different cell con-
centrations were used to generate a standard curve which 
was used to calculate the cell number per well at each time 
point. Changes in cell number were fitted using GraphPad 
Prism 5 software (GraphPad Software, Inc., La Jolla, CA), 
where the normal logarithm of cell number against time re-
sulted in straight line through the exponential growth phase. 
The slope of this line was calculated in order to get the 
maximum specific growth rate [16]. 
Specific ALP Assay 
As ALP activity is critical for calcification [17], the ef-
fect of osteogenic supplements on the ALP activity of HGF 
was quantified. Cultured HGF were washed with HBSS and 
lysed using ALP buffer containing 0.5 M 2-amino-2-
methylpropan-1-ol and 0.1% (v/v) Triton-X100 at pH 10.5. Osteogenic induction of HGF Cells  The Open Dentistry Journal, 2011, Volume 5     141 
After two hours, 100 L from each lysate was added in du-
plicates into 96-well plates and a 100 L of 2 mg/mL ALP 
substrate p-NPP was added to the cell lysate. The absorbance 
of the colored product was then quantified at 405 nm at peri-
odic intervals for up to 20 minutes. The ALP activity was 
presented as p-NPP formed for every minute 
(mmol/min/mL), and normalized by the total DNA content 
(g DNA/mL) of each lysate to attain the specific ALP activ-
ity (ALP/DNA). DNA concentrations were determined using 
the CyQUANT DNA kit in accordance with the manufac-
turer’s instructions [16]. 
Reverse Transcription Polymerase Chain Reaction   
(RT-PCR) Analyses 
HGF were harvested at week 3 and week 4 with Trizol
® 
Reagent and stored at -20°C. Extraction of RNA was per-
formed using the RNeasy Mini Kit and according to the 
manufacturer’s guidelines. Then, total RNA content was 
fluorometrically quantified at  excitation: 480 nm and  emission: 
527 nm with the SYBR Green dye. Subsequently, 0.3 μg of 
the extracted RNA were consumed for the reverse transcrip-
tion (RT) reaction using the Omniscript kit. Finally, the re-
sulting cDNA was used as a template for the Polymerase 
Chain Reaction (PCR) amplification for the genes of interest, 
namely; OPN, OCN, with the housekeeping gene glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) used as the 
internal control. Specific oligonucleotide primer sequences 
were obtained from the literature, and synthesized as fol-
lows: 
GAPDH (158 bp; [18])  Forward: 5': CTGAACGGGAAGC-
TCACTGG-3' 
  Reverse: 5': TAGCCCAGGATGC-
CCTTGAG-3' 
OPN (126 bp; [19])  Forward:  5':  CCAAGTAAGTC-
CAACGAAAG -3 
  Reverse: 5': GGTGATGTCCTCG-
TCTGTA -3' 
OCN (315 bp; [19])  Forward:  5':  GGCAGCGAGGTA-
GTGAAGA-3 
  Reverse: 5': CTGGAGAGGAG-
CAGAACTG-3' 
The PCR conditions employed for all primers were as 
follow: denaturation (95
C for 1 min), annealing (58
C for 1 
min), and extension (72
C for 1 min), with 35 cycles of am-
plification. The relative gene-expression was quantified us-
ing densitometry of the respective PCR products (OPN 126 
bp, OCN 315 bp, and GAPDH 158 bp). Alpha Innotech bio-
imaging system (Alpha Innotech Corp., San Leandro, CA) 
were utilized to photograph ethidium bromide–stained 2% 
agarose gels. Finally, the densitometry values obtained for 
OCN, OPN, and BSP were normalized with GAPDH densi-
tometry value, which are presented in Fig. (4B and C). 
Von Kossa Staining 
HGF treated with or without osteogenic media were 
rinsed with cold PBS after week 3 and week 4, and fixed in 
10% formalin for 30 minutes at room temperature. The cells 
were then rinsed twice with distilled water and incubated in 
2% silver nitrate in the dark for 10 minutes. The silver nitrate 
solution was rinsed away 3 times with distilled water, ex-
posed to bright light for 15 minutes, and dehydrated in 100% 
ethanol. Calcified extracellular matrix was stained brown-
black [20]. 
Calcium Assay 
Wells containing HGF lysates from the ALP Assay were 
washed twice with HBSS and 0.5 mL of HCl (0.5 M) was 
added overnight to dissolve the formed mineral. Samples 
were then stored at 4°C until analysis. Aliquots (20 l) of 
each sample were added to 50 μL of a solution containing 
0.028 M 8-hydroxyquinoline and 0.5% (v/v) sulfuric acid, 
plus 0.5 mL of a solution containing 3.7  10
–4 M o-
cresolphthalein and 1.5% (v/v) AMP (2-amino-2-methyl-
propan-1-ol). The absorbance was measured spectropho-
tometrically at 570 nm. Calcium standards was utilized to 
generate the standard curve and to calculate calcium concen-
tration in each sample which was expressed in terms of 
mg/dL [21]. 
Statistical Analysis 
All assays were performed in triplicate for each treatment 
at each time point and the results were expressed as mean ± 
standard deviation (SD). Data were analyzed with one-way 
analysis of variance (ANOVA) using SPSS version 12.0 
software package (SPSS, Chicago, IL, USA). Intergroup 
differences were determined using the Boneferroni post-hoc 
test, and statistical significance was defined by p-values < 
0.05. 
RESULTS 
Cell Viability and Growth 
The MTT assay showed a gradual increase in cell viabil-
ity during the 4 week study period, in particular between 
week 2 and week 3 (Fig. 1). There was no effect of Dex on 
cell viability when Dex concentration was varied from 0.01 
to 10 μM.  
 
Fig. (1). Effect of Dex concentration on cell viability as measured 
by the MTT assay after weeks 1, 2, 3, and 4. Each point represents 
mean ± SD of triplicate wells. There was no effect of Dex on HGF 
cell viability at any time point. 
Based on the hexosaminidase assay, changes in HGF cell 
number as function of time are summarized in Fig. (2). Sig-
moid growth curves consisting of a lag phase (approximately 
up to day 4), exponential growth phase (approximately day 5 
to day 10) and stationary phase (after day 10) were evident 
0
1
2
3
4
Week 1 Week 2 Week 3 Week 4 
M
T
T
 
a
b
s
o
r
b
a
n
c
e
0  µM Dex 0.01 µM Dex 0.1 µM Dex
0.5 µM Dex 1 µM Dex 10 µM Dex142     The Open Dentistry Journal, 2011, Volume 5  Mostafa et al. 
for all study groups. All Dex concentrations tested gave a 
similar lag phase as compared to the control group (0 μM 
Dex). The growth rates of HGF treated with increasing Dex 
concentration were also similar; the doubling times were 17, 
14.5, 16, 13, 16, and 15 hours when Dex concentrations were 
0, 0.01, 0.1, 0.5, 1, and 10 M, respectively. The final cell 
numbers attained were also similar in all study groups. 
Specific ALP Activity 
The specific ALP activity in control HGF cells was ini-
tially (week 1) lower than the HGF cells treated with Dex, 
where differences were significantly increased for the 0.1 
and 0.5 M Dex concentration (p<0.01, Fig. 3). At weeks 2, 
3 and 4, the specific ALP activity of HGF in all Dex treat-
ment groups were statistically decreased compared to the 
untreated control cells (p<0.001). For Dex treated HGF cells, 
the specific ALP activity was measured to be the highest in 
the 0.1 M Dex concentration group, reaching statistically 
significant levels on week 2 (p<0.01 as compared to 1 and 10 
M Dex) and week 4 (p<0.05 as compared to 10 M Dex).  
Expression of OPN and OCN by HGF 
The results of RT-PCR analysis for the expression of 
OPN and OCN are summarized in Fig. (4). The HGF cells 
treated with Dex demonstrated significant up-regulation of 
both OPN (Fig. 4B) and OCN (Fig. 4C). The expressions of 
OPN and OCN were similar; Dex concentrations of 0.1 M 
and 0.5 M stimulated OPN and OCN expression by week 3 
(p<0.001 and p<0.01 respectively as compared to other 
treatment groups). Dex concentrations of 0.01 M, 0.1 M 
and 0.5 M stimulated OPN and OCN expression by week 4 
(p<0.01 as compared to 0, 1 and 10 M Dex). However, fur-
ther increases in Dex concentration did not increase OPN 
and OCN expression for any time point. 
Von Kossa Staining and Calcification 
   HGF cells stimulated with Dex concentrations of 0.1 
M and 0.5 M Dex stained positively for calcification after 
3 and 4 weeks of culture (Fig. 5). While cells treated with 
 
Fig. (2). Effect of Dex concentration on HGF cell growth rate. Each 
point represents the mean from six wells at each time point. There 
was no apparent effect of Dex on the cell growth pattern.  
 
Fig. (3). Effect of Dex concentration on the cellular specific ALP 
activity (ALP/DNA) after 1, 2, 3, and 4 weeks. Each bar represents 
the mean ± SD of triplicate wells. Dex at 0.1 and 0.5 μM stimulated 
ALP activity in the first week (*: p<0.01 as compared to 0 μM 
Dex), but subsequent ALP was reduced in the presence of Dex. (**: 
p<0.001 as compared to 0 μM Dex). Dex at 0.1 μM maintained 
higher ALP at week 3 (: p<0.05 as compared to 1 and 10 μM Dex) 
and week 4 (#: p<0.05 as compared to 10 μM Dex). 
 
Fig. (4). A. Effect of Dex concentration on the cellular mRNA expression of OPN and OCN by HGF cells after 3 and 4 weeks. (1) 0 μM 
Dex, (2) 0.01 μM Dex, (3) 0.1 μM Dex, (4) 0.5 μM Dex, (5) 1 μM Dex and (6) 10 μM Dex. RT-PCR bands from a representative well for 
each sample is shown. B and C. Densitometric analyses of OPN and OCN mRNA expression at week 3 and 4 after normalization with 
GAPDH. Results represent average ± SD of triplicate wells at each time point. Dex concentrations of 0.1 and 0.5 M stimulated OPN and 
OCN expression by week 3 (**: p<0.001 and *: p<0.01 as compared to other treatment groups). Dex concentrations of 0.01, 0.1 and 0.5 M 
stimulated OPN and OCN expression by week 4 (*: p<0.01 and **: p<0.001 as compared to 0, 1 and 10 M Dex).  
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0.01  M Dex did not stain positively for calcification on 
week 3, longer cultures (week 4) yielded positive staining for 
those cells. Treatments with higher Dex concentrations (1 
and 10 M) did not yield any calcification, as evidenced by 
the Von Kossa staining. 
Based on the spectroscopic calcium assay, the extent of 
calcification was significantly increased in HGF treated with 
0.1 and 0.5 M Dex (p<0.001) as compared to the other 
groups at week 3 (Fig. 6). By week 4, the extent of calcifica-
tion was highest with osteogenic media containing 0.1 M 
Dex (p<0.05 compared to 0.01 M and 0.5 M Dex concen-
trations and p<0.001 as compared to other groups), followed 
by 0.01 M and 0.5 M Dex groups (p<0.01). This pattern 
was consistent with the Von Kossa staining results. 
DISCUSSION AND CONCLUSIONS 
Periodontal therapies aim to restore the lost alveolar 
bone. The fibroblasts are responsible for connective tissue 
matrix synthesis and have essential roles in the development, 
regeneration and function of the tooth supporting apparatus 
[22]. Although the capacity for human PDL cells to differen-
tiate into osteogenic linage (with subsequent mineralized 
tissue formation) has been reported, the osteogenic capacity 
of the anatomically adjacent HGF is still controversial [13-
15]. Two studies [13, 14] reported that osteogenic treatments 
containing 0.1 μM Dex could induce osteogenic differentia-
tion and in vitro mineralization in human PDL cells, but not 
in HGF. Similarly, another report [23] showed that treatment 
with 0.01 M Dex resulted in mineralization in human PDL 
cells, but not in HGF. However, another study [15] demon-
strated the positive osteogenic induction of HGF with 0.01 
M Dex in 25% of HGF samples (3 out of 12), based on Von 
Kossa staining and OCN synthesis. Therefore, our study was 
undertaken to evaluate the in vitro changes in HGF for select 
osteogenic biomarkers following treatment with different 
Dex concentration between 0.01 and 10 μM. 
Osteogenic treatment of HGF cells should exert little or 
no damage to the cells, ensuring their robust proliferation 
and differentiation to obtain a sufficient cell mass for ther-
apy. In previous reports, 0.01 μM [15] and 0.1 μM Dex [13, 
14] did not result in growth inhibition or toxicity, although a 
wider range of Dex concentrations was not been evaluated in 
those studies. We measured the viability (using the MTT 
Assay) of HGF treated with increasing concentrations of 
Dex. Dex did not affect HGF cell viability in either a time- 
or dose-dependent manner. This finding was also confirmed 
by the growth rates, which showed no significant changes 
when cells were treated with osteogenic supplement 
containing increasing Dex concentrations against the control 
group. 
The osteogenic differentiation in HGF cultures was as-
sessed based on specific ALP activity, mRNA expression for 
select extracellular matrix proteins (OPN and OCN), and 
extent of mineralization. ALP is an early marker for os-
teogenic differentiation that augment calcification through 
the hydrolysis of pyrophosphate and ATP, which inhibit cal-
cification, and is crucial for phosphate production, needed 
for the crystallization of hydroxyapatite [17]. In our study, 
HGF exhibited a significant increase in the specific ALP 
activity after treatment with osteogenic supplements contain-
ing 0.1 and 0.5 M Dex compared to the untreated control 
group, initially after one week of culture. Subsequently, 
 
Fig. (5). Von Kossa staining of HGF cells after 3 and 4 weeks of 
osteogenic treatments. Note the higher calcification of HGF cul-
tures treated with 0.01 (week 4), 0.1 (week 3 and 4) and 0.5 μM 
Dex (week 3 and 4). 
 
Fig. (6). Effect of Dex concentration on calcification of HGF cells 
after 3 and 4 weeks. Each bar represents the mean ± SD of triplicate 
wells. Significant mineralization was present for 0.1 and 0.5 M 
Dex at week 3 (**: p<0.001 as compared to other groups) and 0.01, 
0.1 and 0.5 M Dex at week 4 (**: p<0.001 and *: p<0.01 as com-
pared to 0, 1 and 10 M Dex). 
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there was a significant reduction in the specific ALP activity 
with Dex treatment. Such reduction in the ALP activity 
might be due to decrease in the number of osteoprogenitor 
cells in the cultured HGF and suggesting early maturation of 
the osteogenic phenotype based on this biomarker. In con-
trast, untreated HGF maintained a basal level of ALP activity 
over the 28 day culture duration compared to Dex-treated 
HGF. These results are in agreement with Ivanovski et al. [8] 
who reported that HGF cells expressed ALP under normal 
culture condition without Dex stimulation. 
OPN and OCN are indicators for early and late phase of 
osteogenic differentiation, respectively [14]. OCN is re-
garded as the most specific matrix protein produced by os-
teoblasts during the onset of matrix mineralization as it binds 
hydroxyapatite [24, 25]. Ivanovski  et al. [8] reported that 
OPN and OCN were not detected in HGF cultured in basic 
medium at early stages. Another study [26] treated HGF with 
osteogenic medium containing 50 g/ml ascorbic acid, 10 
mM ß-GP and 0.1 μM Dex (similar to the osteogenic me-
dium used in our study) and could not detect OPN expres-
sion in HGF at day 14. Therefore, we performed the RT-
PCR analysis on week 3 and 4 based on the available litera-
ture. The mRNA expression levels of both OPN and OCN 
were significantly increased with Dex treatment, with opti-
mal effect observed at 0.1 and 0.5 M Dex. Whereas OPN 
and OCN were previously shown to be expressed at different 
stages of mineralization [27], our results indicated a similar 
expression pattern for the two proteins. We only investigated 
late stages of mineralization (3 and 4 weeks) and utilizing an 
earlier time point for RT-PCR analysis might reveal such 
differences. Consistent with the increased expression of OPN 
and OCN, the HGF cells underwent increased mineralization 
in those treatment groups. Our mineralization data were 
similar to the study by Zhou et al. [15] that demonstrated 
positive osteogenic induction of HGF with 0.01 M Dex in 
25% of HGF samples (3 out of 12), based on Von Kossa 
staining and OCN synthesis. However, Arceo et al. [13] only 
reported mineralization of HGF cells treated with osteogenic 
supplements containing 0.1 M Dex for days 20 to 30 based 
on Von Kossa staining, although other markers such as ALP 
activity and OCN expression were not assessed in their 
study. Pi et al. [14], on the other hand, reported a dramatic 
increase in osteonectin expression by HGF cells but not OPN 
and BMP-2, after 14 days of osteogenic treatment containing 
0.1 M Dex [14]. In addition, they did not demonstrate any 
increase in ALP activity or mineralization. It may be noted 
that in their study [14], the ALP activity was analyzed until 
day 7, osteogenic marker expression at only one time point 
(day 14), and mineralization only until day 21. Our study 
was more thorough in that respect, but it is possible the dif-
ferences between our results and those studies
 might also be 
related to the heterogeneity of human adult cells and the par-
ticular location of the harvested tissues. It is known that the 
characteristics of human cells induced for osteogenic differ-
entiation vary depending on the anatomical site and the do-
nor's age and gender [28]. For example, Carnes et al. [29] 
reported that HGF cells from different donors showed differ-
ent ALP levels, and showed that cells preselected with high 
basal ALP levels demonstrated the ability to mineralize in 
culture as determined by OCN production and Von Kossa 
staining while others did not. The HGFs used in our study 
and in the study by Zhou et al. [15] showed significant ALP 
levels under normal culture condition which could suggest 
their inherent osteogenic potential.  
The results of our study suggest that under an appropriate 
conditioning environment (i.e., osteogenic supplementation 
with an optimal Dex concentration), gingival fibroblasts 
could be induced into an osteogenic phenotype. The results 
consistently showed osteogenic effect of Dex on HGF cells 
to be maximal at 0.1 and 0.5 M Dex, and higher Dex con-
centrations caused a down regulation of osteogenic effects 
observed at lower concentrations. A possible explanation for 
the down-regulation of the osteogenic effect of Dex on HGF 
at 1 and 10 M is that high Dex concentration increased the 
population of other cell lineage in the cultured HGF which 
might explain the reduction in osteogenic potential when 
Dex concentration was increased beyond 500 nM. Therefore, 
further studies should be performed to better understand and 
characterize the differentiation of HGF under different con-
ditions. Such suitably modified HGF cells could prove prom-
ising for developing cell-based tissue engineering therapies 
for the regeneration of supporting alveolar bone.  
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